Suppr超能文献

局部晚期下咽癌的治疗结果及预后因素

Treatment results and prognostic factors in locally advanced hypopharyngeal cancer.

作者信息

Lee Moon-Sing, Ho Hsu-Chueh, Hsiao Shih-Hsuan, Hwang Juen-Haur, Lee Ching-Chih, Hung Shih-Kai

机构信息

Department of Radiation Oncology, Buddhist Dalin Tzu Chi General Hospital, Dalin, Chiayi, Taiwan.

出版信息

Acta Otolaryngol. 2008 Jan;128(1):103-9. doi: 10.1080/00016480701387116.

Abstract

CONCLUSIONS

We suggest that concurrent chemoradiation (CCRT) is an effective definitive treatment for patients with advanced hypopharyngeal carcinoma who are unfit for or refuse surgery. A high dose of radiation (> 70 Gy) should be given to achieve acceptable local control rates and survival.

OBJECTIVES

The purpose of this retrospective study was to compare the treatment results of locally advanced hypopharyngeal carcinoma with two different protocols.

PATIENTS AND METHODS

From December 1995 to December 2004, 74 patients with locally advanced hypopharyngeal cancer were treated with CCRT or surgery plus postoperative radiotherapy (SRT). Their treatment results were reviewed by retrospective analysis. The study points included outcome, toxicity, and prognostic factors.

RESULTS

There was no significant difference in T and N status between the two treatment groups, nor were there significant differences in overall or disease-free survival or the incidence of distant metastasis (p >0.05). In the CCRT group and SRT group, the estimated 3-year overall survival was 39% and 44%, respectively. The SRT group had better local control than the CCRT group (p <0.05). Relatively, 27% patients retained their larynx function for more than 2 years in the CCRT group. Radiation doses >70 Gy yielded significantly better survival and local control than doses <70 Gy (p <0.05).

摘要

结论

我们认为,同步放化疗(CCRT)是治疗不适合或拒绝手术的晚期下咽癌患者的一种有效的确定性治疗方法。应给予高剂量放疗(>70 Gy)以实现可接受的局部控制率和生存率。

目的

本回顾性研究的目的是比较两种不同方案治疗局部晚期下咽癌的疗效。

患者和方法

1995年12月至2004年12月,74例局部晚期下咽癌患者接受了同步放化疗或手术加术后放疗(SRT)。通过回顾性分析对他们的治疗结果进行评估。研究要点包括疗效、毒性和预后因素。

结果

两个治疗组在T和N分期上无显著差异,总生存率、无病生存率或远处转移发生率也无显著差异(p>0.05)。在同步放化疗组和手术加术后放疗组中,估计3年总生存率分别为39%和44%。手术加术后放疗组的局部控制情况优于同步放化疗组(p<0.05)。相对而言,同步放化疗组中27%的患者保留喉功能超过2年。放疗剂量>70 Gy的患者在生存率和局部控制方面显著优于剂量<70 Gy的患者(p<0.05)。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验